NHS England secures new deal for all three UK-licensed cystic fibrosis medicines

NHS England secures new deal for all three UK-licensed cystic fibrosis medicines

NHS England has today announced it has secured a definitive agreement to make three of the UK-licensed cystic fibrosis medicines available on the NHS.  

The new deal with Vertex Pharmaceuticals will see patients will now have full access to Orkambi, Symkevi and Kalydeco, and around 5,000 people may now take up these treatments.

With no cap on patient numbers, every patient in England who might benefit can now get these treatments, and within 30 days clinicians will be able to begin prescribing these drugs.

NHS England has been able to finalise this negotiation because the company agreed to confidential commercial terms that ‘constitute good value for British taxpayers’, and has agreed to submit its drugs for full NICE appraisal.

The agreement provides access to all three drugs for current licensed indications, as well as future license extensions too.

Announcing the agreement, NHS chief executive Simon Stevens said: “The UK has the second highest prevalence of cystic fibrosis of any country in the world, so today is an important and long hoped for moment for children and adults living with cystic fibrosis.

“That fact also means that any drug company wanting to succeed commercially in this field needs to work constructively with the NHS.

“I’m pleased that Vertex has now agreed a deal that is good for our patients and fair to British taxpayers.”

The agreement has also been backed by NICE, and a key part of the deal is that Vertex will submit its full portfolio including in due course its new triple therapy to NICE for comprehensive appraisal.

Health secretary Matt Hancock said: “Some wonderful news this morning. We’ve agreed a deal to provide Orkambi and other lifesaving Cystic Fibrosis drugs on the NHS. The deal is great value for money for the NHS, and crucially, will improve thousands of lives.

“This deal – on the back of several others this summer – shows why we get some of the best value drugs in the world, and is another reason to be so proud of our NHS.”

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all